Botulinum toxin type A enhances the outcome of fractional resurfacing of the cheek.
Fractional resurfacing and fractionally ablative (CO2) resurfacing have become increasingly popular in recent years. They hold the promise of delivering skin rejuvenation with fewer risks and less downtime than traditional ablative resurfacing. Despite the popularity of the procedures and the trend toward synergistic activity in aesthetic dermatology, there is little documentation regarding the use of botulinum toxins and fractional resurfacing for the midface. This report discusses the use of botulinum toxin type A and fractional resurfacing for the cheek area. Although it is a limited, single case report, it provides insight into the potential for this combination and may serve as a stimulus for a large, well-controlled study to evaluate the use of toxins in this and similar areas.
Kenneth
K
Beer
Jill
J
Waibel
D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003357:Cosmetic Techniques; D005260:Female; D006801:Humans; D053685:Laser Therapy / Q000379:methods*; D054020:Lasers, Gas / Q000627:therapeutic use*; D008875:Middle Aged; D012060:Rejuvenation; D015595:Skin Aging / Q000187:drug effects*
D019274:Botulinum Toxins, Type A